MoonLake Immunotherapeutics
For the period ended Jun 30, 2025. Filed Aug 5, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2025 · Filed Aug 5, 2025
MLTX$12.62+9.5%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Changes In E
CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY
| Class A Ordinary Shares · Class C Ordinary Shares · Additional Paid-In Capital · Accumulated Deficit · Accumulated Other Comprehensive Income · Total Shareholders' Equity · Noncontrolling Interests · Total Equity | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| (in thousands except share data) · Shares · Amount · Shares · Amount | ||||||||||
| Balance at January 1, 2024 | 60,466,453 | $6 | 2,505,476 | $— | $609,969 | $(116,657) | $2,358 | $495,676 | $17,815 | $513,491 |
| Share-based compensation under the ESPP and Equity Incentive Plan | — | — | — | — | 1,693 | — | — | 1,693 | (16) | 1,677 |
| Buyback of unvested MoonLake AG Common Shares by MoonLake AG into treasury following an employee contract termination (Note 12) | — | — | — | — | 113 | — | 1 | 114 | (114) | — |
| Capital injection from MoonLake to MoonLake AG (Note 12) | — | — | — | — | (4,667) | — | — | (4,667) | 3,057 | (1,610) |
| Cancellation of MoonLake Class C Ordinary Shares following an employee contract termination in MoonLake AG (Note 12) | — | — | (16,853) | — | — | — | — | — | — | — |
| Issuance of Class A Ordinary Shares, net of transaction costs (Note 12) | 914,828 | — | — | — | 52,540 | — | — | 52,540 | — | 52,540 |
| Net loss for the three months ended March 31, 2024 | — | — | — | — | — | (13,673) | — | (13,673) | (302) | (13,975) |
| Other comprehensive income | — | — | — | — | — | — | 257 | 257 | 6 | 263 |
| Conversion of MoonLake Class C Ordinary Shares into Class A Ordinary Shares | 1,493,356 | — | (1,493,356) | — | 10,537 | — | 76 | 10,613 | (10,613) | — |
| Balance at March 31, 2024 | 62,874,637 | $6 | 995,267 | $— | $670,185 | $(130,330) | $2,692 | $542,553 | $9,833 | $552,386 |
| Share-based compensation under the ESPP and Equity Incentive Plan | — | $— | — | $— | $1,813 | $— | $— | $1,813 | $15 | $1,828 |
| Other comprehensive loss | — | $— | — | $— | $— | $— | $564 | $564 | $12 | $576 |
| Net loss for the three months ended June 30, 2024 | — | $— | — | $— | $— | $(24,267) | $— | $(24,267) | $(492) | $(24,759) |
| Balance at June 30, 2024 | 62,874,637 | $6 | 995,267 | $— | $671,998 | $(154,597) | $3,256 | $520,663 | $9,368 | $530,031 |
CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY
| Class A Ordinary Shares · Class C Ordinary Shares · Additional Paid-In Capital · Accumulated Deficit · Accumulated Other Comprehensive Income · Total Shareholders' Equity · Noncontrolling Interests · Total Equity | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| (in thousands except share data) · Shares · Amount · Shares · Amount | ||||||||||
| Balance at January 1, 2025 | 63,077,431 | $6 | 841,269 | $— | $677,415 | $(235,593) | $4,997 | $446,825 | $6,566 | $453,391 |
| Share-based compensation under the ESPP and Equity Incentive Plan | — | — | — | — | 2,279 | — | — | 2,279 | 11 | 2,290 |
| Conversion of MoonLake Class C Ordinary Shares into Class A Ordinary Shares | 111,949 | — | (111,949) | — | 841 | — | 10 | 851 | (851) | — |
| Options exercised and converted under the Employee Stock Option Plan, net of stamp duty fee | 93,347 | — | — | — | 129 | — | — | 129 | (9) | 120 |
| Issuance of Restricted Stock Awards under the Equity Incentive Plan | 191,526 | — | — | — | — | — | — | — | — | — |
| Net loss for the three months ended March 31, 2025 | — | — | — | — | — | (39,944) | — | (39,944) | (615) | (40,559) |
| Other comprehensive loss | — | — | — | — | — | — | (2,620) | (2,620) | (41) | (2,661) |
| Balance at March 31, 2025 | 63,474,253 | $6 | 729,320 | $— | $680,664 | $(275,537) | $2,387 | $407,520 | $5,061 | $412,581 |
| Share-based compensation under the ESPP and Equity Incentive Plan | — | $— | — | $— | $3,298 | $— | $— | $3,298 | $11 | $3,309 |
| Net loss for the three months ended June 30, 2025 | — | $— | — | $— | $— | $(55,220) | $— | $(55,220) | $(831) | $(56,051) |
| Other comprehensive loss | — | $— | — | $— | $— | $— | $(1,867) | $(1,867) | $(28) | $(1,895) |
| Balance at June 30, 2025 | 63,474,253 | $6 | 729,320 | $— | $683,962 | $(330,757) | $520 | $353,731 | $4,213 | $357,944 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.